{"title":"Survival Predictors in Obstructive Colorectal Cancer: A Combined Clinical, Inflammatory, and Histopathological Approach.","authors":"Ahmet Tarik Harmantepe, Adem Şentürk","doi":"10.21873/invivo.14041","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Obstructive colorectal cancer (oCRC) accounts for a significant proportion of colorectal malignancies and is associated with poor prognosis and higher perioperative morbidity. Inflammation-based biomarkers have emerged as potential predictors of survival in various cancers. However, their prognostic role in oCRC remains unclear.</p><p><strong>Patients and methods: </strong>This retrospective study included patients who underwent surgery for histopathologically confirmed oCRC at Sakarya University Training and Research Hospital between January 2015 and February 2024. Preoperative systemic inflammatory markers-C-reactive protein-to-albumin ratio (CAR), lymphocyte-to-C-reactive protein ratio (LCR), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory index (SII), and HALP score-were analyzed. Overall survival was recorded, and statistical analyses were performed.</p><p><strong>Results: </strong>Among the inflammatory markers, CAR, LCR, and PNI were significantly associated with overall survival at 1, 3, and 5 years (<i>p</i> <0.05). LCR demonstrated the highest sensitivity and specificity in predicting mortality. Patients with higher CAR and lower PNI values had significantly poorer outcomes.</p><p><strong>Conclusion: </strong>Preoperative systemic inflammatory markers, particularly LCR, CAR, and PNI, are valuable prognostic indicators in patients with oCRC. These easily obtainable markers may help guide clinical decision-making and improve individualized patient management.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2419-2428"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223651/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Obstructive colorectal cancer (oCRC) accounts for a significant proportion of colorectal malignancies and is associated with poor prognosis and higher perioperative morbidity. Inflammation-based biomarkers have emerged as potential predictors of survival in various cancers. However, their prognostic role in oCRC remains unclear.
Patients and methods: This retrospective study included patients who underwent surgery for histopathologically confirmed oCRC at Sakarya University Training and Research Hospital between January 2015 and February 2024. Preoperative systemic inflammatory markers-C-reactive protein-to-albumin ratio (CAR), lymphocyte-to-C-reactive protein ratio (LCR), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory index (SII), and HALP score-were analyzed. Overall survival was recorded, and statistical analyses were performed.
Results: Among the inflammatory markers, CAR, LCR, and PNI were significantly associated with overall survival at 1, 3, and 5 years (p <0.05). LCR demonstrated the highest sensitivity and specificity in predicting mortality. Patients with higher CAR and lower PNI values had significantly poorer outcomes.
Conclusion: Preoperative systemic inflammatory markers, particularly LCR, CAR, and PNI, are valuable prognostic indicators in patients with oCRC. These easily obtainable markers may help guide clinical decision-making and improve individualized patient management.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.